Malik, Cytokinetics EVP, sells $72,680 in shares
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cytokinetics Inc (CYTK)
Cytokinetics Inc stock price live, this page displays NASDAQ CYTK stock exchange data. View the CYTK premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cytokinetics Inc real time stock price chart below.
What Is the Cytokinetics Inc Stock Price Today?
The Cytokinetics Inc stock price today is 35.14.
What Is the Stock Symbol for Cytokinetics Inc?
The stock symbol for Cytokinetics Inc is ""CYTK.""
What Stock Exchange Does Cytokinetics Inc Trade On?
Cytokinetics Inc is listed and trades on the NASDAQ stock exchange.
Is Cytokinetics Inc a Good Stock to Buy?
Determining whether Cytokinetics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CYTK quote. (ISIN: US23282W6057)
What Is the Cytokinetics Inc Stock Price Today?
The Cytokinetics Inc stock price today is 35.14.
What Is the Stock Symbol for Cytokinetics Inc?
The stock symbol for Cytokinetics Inc is ""CYTK.""
What Stock Exchange Does Cytokinetics Inc Trade On?
Cytokinetics Inc is listed and trades on the NASDAQ stock exchange.
Is Cytokinetics Inc a Good Stock to Buy?
Determining whether Cytokinetics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CYTK quote. (ISIN: US23282W6057)
Currency in USD
35.14
-1.02(-2.82%)
Closed·
After Hours
35.05-0.09(-0.26%)
·
Fair Value
An estimate of a Cytokinetics Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
34.57
35.91
52 wk Range
29.31
59.39
CYTK Scorecard
Full Analysis
Analysts anticipate sales decline in the current year
CYTK is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Cytokinetics Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
34.5735.91
52 wk Range
29.3159.39
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CYTK Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Cytokinetics Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
72.11
Upside
+105.19%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Cytokinetics CEO Robert Blum sells $169,000 in stock
- Investing.com
- Malik, Cytokinetics EVP, sells $72,680 in shares
- Investing.com
- Cytokinetics (CYTK) CEO Blum sells $190k in stock
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Cytokinetics Inc Company Profile
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Cytokinetics Inc SWOT Analysis
Aficamten's Promise | Explore how Cytokinetics' lead candidate, aficamten, is poised to revolutionize hypertrophic cardiomyopathy treatment with its differentiated profile and broad efficacy |
Pipeline Potential | Delve into Cytokinetics' diverse R&D pipeline, showcasing the company's commitment to muscle biology across multiple therapeutic areas beyond HCM |
Market Dynamics | Analyst price targets range from $53 to $120, reflecting varied perspectives on Cytokinetics' potential in the multi-billion dollar HCM market |
Strategic Outlook | Uncover Cytokinetics' Vision 2030 strategy, balancing near-term focus on aficamten with long-term growth through pipeline expansion and market positioning |
Cytokinetics Inc Earnings Call Summary for Q1/2025
- Q1 2025 net loss of $161.4M ($1.36/share); revenue of $1.6M missed $3.6M forecast; stock down 7.31% after-hours to $34.2
- R&D expenses up to $99.8M; company focuses on advancing aficamten NDA for OHCM treatment with FDA approval expected Dec 2025
- Cash position at $1.1B; full-year 2025 GAAP operating expenses projected between $670M-$710M
- CEO confident in aficamten approval and positioning; potential European market entry in 2026
- Analysts focused on regulatory pathway for aficamten, particularly REMS submission; company reiterates approval confidence
Last Updated: 06/05/2025, 23:18
Read Full TranscriptCompare CYTK to Peers and Sector
Metrics to compare | CYTK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCYTKPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.8x | −1.1x | −0.5x | |
PEG Ratio | −3.64 | −0.06 | 0.00 | |
Price/Book | −15.8x | 2.3x | 2.6x | |
Price / LTM Sales | 218.4x | 9.8x | 3.3x | |
Upside (Analyst Target) | 93.7% | 303.2% | 43.5% | |
Fair Value Upside | Unlock | 20.0% | 6.9% | Unlock |
Analyst Ratings
17 Buy
4 Hold
0 Sell
Ratings:
21 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 72.11
(+105.19% Upside)
Earnings
Latest Release
May 06, 2025
EPS / Forecast
-1.36 / -1.37
Revenue / Forecast
1.58M / 3.60M
People Also Watch
FAQ
What Stock Exchange Does Cytokinetics Inc Trade On?
Cytokinetics Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Cytokinetics Inc?
The stock symbol for Cytokinetics Inc is "CYTK."
What Is the Cytokinetics Inc Market Cap?
As of today, Cytokinetics Inc market cap is 4.19B.
What Is Cytokinetics Inc's Earnings Per Share (TTM)?
The Cytokinetics Inc EPS (TTM) is -5.30.
When Is the Next Cytokinetics Inc Earnings Date?
Cytokinetics Inc will release its next earnings report on 29 Oct 2025.
From a Technical Analysis Perspective, Is CYTK a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Cytokinetics Inc Stock Split?
Cytokinetics Inc has split 1 times.
How Many Employees Does Cytokinetics Inc Have?
Cytokinetics Inc has 498 employees.
What is the current trading status of Cytokinetics Inc (CYTK)?
As of 07 Aug 2025, Cytokinetics Inc (CYTK) is trading at a price of 35.14, with a previous close of 36.16. The stock has fluctuated within a day range of 34.57 to 35.91, while its 52-week range spans from 29.31 to 59.39.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.